Inceptor Bio is developing next-generation cell therapy programs with a focus on chimeric antigen receptor (CAR) constructs, which have novel mechanisms to enhance immune cell activation and endurance in the tumor microenvironment (TME). Inceptor Bio provides best-in-class therapies – CAR-T, CAR-M, CAR-NK platform technologies – to enhance the likelihood of success against difficult-to-treat cancers.


Kineticos Value Ad

Kineticos, through its consulting arm, has supported various strategy, business development, and scientific consulting projects throughout the growth of Inceptor Bio. Inceptor Bio was founded by Shailesh Maingi, Kineticos Ventures GP member. Inceptor Bio’s team, board of advisors, and scientific advisory board members consist of Kineticos Ventures Operating Partners, Venture Partners, and Strategic Advisors.


Investment Thesis

Team: Leading scientists and executives in Cell and Gene Therapy
Platform: CAR-T, CAR-M, CAR-NK utilizing novel technology platforms licensed from top research universities
Unmet Need: Cancer is the leading cause of death, responsible for 1 out of 6 deaths

Visit Site